Renal impairment is a common problem in patients with multiple myeloma. An early and rapid reduction in serum levels of free light chains (FLCs), achieved with the use of antimyeloma agents or direct removal of FLCs, has been shown to improve renal recovery in these patients. In this Review, the authors provide an update on new and current management approaches for reducing FLC levels in patients with myeloma-related acute kidney injury.
- Colin A. Hutchison
- Joan Bladé
- Christopher Winearls